Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CimetrA in Moderate COVID-19
NCT04802382Phase 3Unknown
- Sponsor
- MGC Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CimetrA in coronavirus disease 2019 (COVID-19), sponsored by MGC Pharmaceuticals. Status: unknown.
02
Drugs
CimetrA
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04802382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802382.